NCT03946878View on ClinicalTrials.gov

Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 13, 2019

Primary Completion Date

February 8, 2026

Study Completion Date

February 8, 2026

Conditions

Blastoid Variant Mantle Cell LymphomaCCND1 Protein OverexpressionCD20 PositiveCD5 PositiveFCER2 NegativePleomorphic Variant Mantle Cell LymphomaRecurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphomat(11;14)(q13;q32)

Interventions

DRUG

Acalabrutinib

Given PO

DRUG

Venetoclax

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER